A Review of Insulin Pen Devices

References

• . Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. General information. http://www.cdc.gov. Accessed March 23, 2010
   Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS 33) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053
   PubMed Web of Science ®Google Scholar
• . Hogan P, Dall T, Nikolov P; American Diabetes Association.Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917–932
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963–1972
   PubMed Web of Science ®Google Scholar
• . Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–86
   PubMed Web of Science ®Google Scholar
• . Cryer PE, Childs BP. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum. 2002;15(1):20–27
   Google Scholar
• . Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26( suppl 3):S18–S24
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR, Lauritzen T, ; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes, Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–2679
   PubMed Web of Science ®Google Scholar
• . Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36–38
   Google Scholar
• . Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20(3):292–298
   PubMed Web of Science ®Google Scholar
• . Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545
   PubMed Web of Science ®Google Scholar
• . Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498–1505
   PubMed Web of Science ®Google Scholar
• . Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91(1):1–9
   PubMed Web of Science ®Google Scholar
• . Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis. 1986;45(2):130–135
   PubMed Web of Science ®Google Scholar
• . Ziegler D, Gries FA, Spüler M, Lessman F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabetes Med. 1993;10( suppl 2):82S–86S
   PubMed Web of Science ®Google Scholar
• . Spollett G. Insulin devices: addressing barriers to insulin therapy with the ideal pen. Diabetes Educator. 2008;34(6):957–960, 963, 967
   PubMed Web of Science ®Google Scholar
• . Bell DS, Clements RS Jr, Perentesis G, Roddam R, Wagenknecht L. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med. 1991;151(11):2265–2269
   PubMedGoogle Scholar
• . Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998;79(1):59–62
   PubMed Web of Science ®Google Scholar
• . Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging. 2001;18(1):31–44
   PubMed Web of Science ®Google Scholar
• . DeWitt DE, Hirsh IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289(17):2254–2264
   PubMed Web of Science ®Google Scholar
• . Levemir (insulin detemir) [package insert]. Princeton, NJ: Novo Nordisk; August 2009
   Google Scholar
• . Novolin N (NPH) [package insert]. Princeton, NJ: Novo Nordisk; June 2009
   Google Scholar
• . Humulin N (NPH) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2007
   Google Scholar
• . Lantus (insulin glargine) [package insert]. Bridgewater, NJ: sanofiaventis; March 2007
   Google Scholar
• . Novolog (insulin asparte) [package insert]. Princeton, NJ: Novo Nordisk; October 2009
   Google Scholar
• . Humalog (insulin lispro) [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2009
   Google Scholar
• . Apidra (insulin glulisine) [package insert]. Bridgewater, NJ: sanofiaventis; February 2009
   Google Scholar
• . Novolin R (regular human insulin) [package insert]. Princeton, NJ: Novo Nordisk; June 2009
   Google Scholar
• . Humulin R (regular human insulin) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2007
   Google Scholar
• . Novolog Mix 70/30 (insulin aspart/insulin aspart protamine) [package insert]. Princeton, NJ: Novo Nordisk; August 2009
   Google Scholar
• . Humalog 75/25 (insulin lispro/insulin lispro protamine) [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2009
   Google Scholar
• . Humalog 50/50 (insulin lispro/insulin lispro protamine) [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2009
   Google Scholar
• . Novolin 70/30 (regular human insulin/human insulin isophane) [package insert]. Princeton, NJ: Novo Nordisk; June 2009
   Google Scholar
• . Humulin 70/30 (NPH/regular human insulin) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2007
   Google Scholar
• . Raskin P, Allen E, Hollander P, ; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265
   PubMed Web of Science ®Google Scholar
• . Kroon L. Overview of insulin delivery pen devices [published online ahead of print August 18, 2009]. J Am Pharm Assoc.
   Google Scholar
• . Novo Nordisk. Novo Nordisk care. http://www.novonordiskcare.com. Accessed March 22, 2010
   Google Scholar
• . Eli Lilly and Company. Insulin pens. http://www.insidehumalog.com. Accessed March 22, 2010
   Google Scholar
• . Sanofi-aventis. OptiClik®. http://www.opticlik.com. Accessed March 22, 2010
   Google Scholar
• . Owen Mumford. Autopen. http://www.owenmumford.com/en/range/6/autopen.html. Accessed March 22, 2010
   Google Scholar
• . Sanofi-aventis. Lantus SoloSTAR® Pen. http://www.lantus.com. Accessed March 22, 2010
   Google Scholar
• . Sanofi-aventis. Apidra SoloSTAR® Pen. http://www.apidra.com. Accessed March 22, 2010
   Google Scholar
• . Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165–174
   PubMed Web of Science ®Google Scholar
• . Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529–538
   PubMed Web of Science ®Google Scholar
• . Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486–496
   PubMed Web of Science ®Google Scholar
• . Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27( suppl B):S89–S100
   PubMed Web of Science ®Google Scholar
• . Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Invest. 2006;26(7):367–401
   PubMed Web of Science ®Google Scholar
• . Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29(4):650–660
   PubMed Web of Science ®Google Scholar
• . Shaghouli AA, Shah BR. The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther. 2009;11(7):439–442
   PubMed Web of Science ®Google Scholar
• . Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948–962
   PubMed Web of Science ®Google Scholar
• . Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712–1725
   PubMed Web of Science ®Google Scholar
• . Asakura T, Seino H, Nakano R, . A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther. 2009;11(10):657–661
   PubMed Web of Science ®Google Scholar
• . Korytowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team.A multicenter, randomized, open-label, comparative, two-period cross over trial of preference, efficacy, and safety profiles of a prefilled disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836–2848
   PubMed Web of Science ®Google Scholar
• . Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347–1357
   PubMed Web of Science ®Google Scholar
• . Magnolti MA, Rayfield EJ. An update on insulin injection devices. Insulin. 2007;2(4):173–181
   Google Scholar
• . Drugstore.com. Drug prices. http://www.drugstore.com. Accessed March 29, 2010
   Google Scholar